EUCTR2004-001563-21-ES进行中（未招募）不适用
A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia - hLL2-18
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or females, 18 years old or greater.
- •2. Documented diagnosis of WM satisfying criteria proposed at 2nd International Workshop on WM, Athens, Greece, 2002.
- •3. Measurable disease, defined as serum monoclonal IgM protein greater than or equal to 1000 mg/dL by electrophoresis.
- •4. Lymphoplasmacytic infiltration of the bone marrow > 10% involvement.
- •5. Failed at least one, but no more than 3, regimen(s) of prior therapy.
- •6. Karnofsky Performance Status (KPS) greater than or equal to 60.
- •7. Minimal life expectancy of 6 months.
- •8. Must be willing and able to give informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant women.
- •2. Lactating women, unless they agree not to breastfeed for a period of 3 months after completing treatment.
- •3. Women of childbearing potential and fertile men who are unwilling to practice birth control during and for a period of 12 weeks after completing treatment.
- •4. Major surgery, radiation, chemotherapy, stem cell transplant, or any other therapy within 4 weeks prior to enrollment and recovered from all treatment-related toxicity.
- •5. Prior therapies must not include more than one prior therapy with rituximab, and patients who were refractory to rituximab are excluded, where refractory is defined as failure to achieve an objective response to rituximab or having progression of disease within 6 months after rituximab.
- •6. Prior therapy with other murine, chimeric, human or humanized monoclonal antibodies, unless HAHA is negative.
- •7. Prior treatment with any other investigational agents, unless follow-up is completed and patient is off study.
- •8. < 2 weeks beyond corticosteroids.
- •9. Hemoglobin < 7.0 g/dL, absolute neutrophil count, < 1000 mm³, platelets < 50,000/mm³, without ongoing transfusional support.
- •10. Serum creatinine > 1.5 X Institutional Upper Limit of Normal (IULN).
- •11. Serum bilirubin > 1.5 X ILUN, Alkaline phosphatase > 1.5 IULN, ALT (SGPT > 1.5 X IULN and/or AST (SGOT) > 1.5 X IULN.
- •12. Other primary malignancy (other than squamous or basal cell skin cancer, or cervical cancer in-situ) within 5 years.
- •13. Known HIV positive or active hepatitis B or C or presence of hepatitis B or C surface antigens.
- •14. Significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.
研究者
相似试验
进行中（未招募）
1 期
Trial of Elotuzumab/Thalidomide/dexamethasone in subjects with Relapsed and/or Refractory Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005121-49-ESBristol-Myers Squibb International Corporation40
进行中（未招募）
1 期
A study of nivolumab in participants with metastatic or unresectable bladder cancermetastatic or unresectable urothelial cancerMedDRA version: 19.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003625-17-SEBristol-Myers Squibb International Corporation323
进行中（未招募）
1 期
A study of nivolumab in participants with metastatic or unresectable bladder cancermetastatic or unresectable urothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003625-17-BEBristol-Myers Squibb International Corporation323
进行中（未招募）
1 期
A study of nivolumab in participants with metastatic or unresectable bladder cancermetastatic or unresectable urothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000017545MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000017499MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000017553MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000061529EUCTR2014-003625-17-PLBristol-Myers Squibb International Corporation323
进行中（未招募）
1 期
A study of nivolumab in participants with metastatic or unresectable bladder cancerEUCTR2014-003625-17-FIBristol-Myers Squibb International Corporation323